Letter to perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe

Category	Detail
Condition	Ventilator-Associated Pneumonia (VAP)
Key Mechanisms	Infection of lower respiratory tract in mechanically ventilated ICU patients, with microbiological pathogens varying by patient population and timing of onset
Target Population	ICU patients on mechanical ventilation, with subgroups including neurocritical, trauma, early-onset VAP patients
Care Setting	Intensive Care Units across Europe

Staphylococcus aureus was the predominant pathogen (26.2%) in the ECRAID-POS-VAP cohort, contrasting with prior studies where Gram-negative bacteria predominate.
The study population included a higher proportion of stroke and trauma patients and early-onset VAP cases, influencing microbiological patterns.
Low microbiological documentation rate (60.8%) may bias pathogen distribution towards easily identified organisms like S. aureus.

Consider patient case-mix and timing of VAP onset when interpreting microbiological data.
Use systematic sampling strategies to improve microbiological yield and reduce selection bias.

Tailor empirical antibiotic therapy based on accurate local epidemiology and patient subgroup characteristics.
Avoid overestimating S. aureus prevalence to prevent inappropriate empirical coverage, especially in settings with predominant multidrug-resistant Gram-negative pathogens.

Perform stratified analyses by VAP onset timing, admission diagnosis, and ICU type to refine pathogen distribution understanding.
Monitor microbiological documentation rates to ensure representative pathogen identification.

Risk of inappropriate empirical antibiotic use if microbiological data are not contextualized by patient population and VAP timing.
Potential under-recognition of multidrug-resistant Gram-negative infections due to low microbiological yield.

ICU patients with ventilator-associated pneumonia, including neurocritical, trauma, and early-onset VAP subgroups

Empirical antibiotic regimens should consider the specific patient case-mix and local pathogen prevalence to optimize coverage and stewardship.

Interpret microbiological findings in VAP with consideration of patient demographics and timing of infection onset.
Employ comprehensive and systematic microbiological sampling to capture accurate pathogen profiles.
Customize empirical antibiotic strategies based on stratified epidemiological data to balance efficacy and antimicrobial stewardship.

Clinical Scorecard: Clinical and Microbiological Trends in Ventilator-Associated Pneumonia Across Europe: Insights from the ECRAID-POS-VAP Study